GB9827103D0 - New cancer treatments - Google Patents

New cancer treatments

Info

Publication number
GB9827103D0
GB9827103D0 GBGB9827103.4A GB9827103A GB9827103D0 GB 9827103 D0 GB9827103 D0 GB 9827103D0 GB 9827103 A GB9827103 A GB 9827103A GB 9827103 D0 GB9827103 D0 GB 9827103D0
Authority
GB
United Kingdom
Prior art keywords
cell lines
prostate cancer
heterogeneity
cancer treatments
new cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9827103.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onyvax Ltd
Original Assignee
Onyvax Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyvax Ltd filed Critical Onyvax Ltd
Priority to GBGB9827103.4A priority Critical patent/GB9827103D0/en
Publication of GB9827103D0 publication Critical patent/GB9827103D0/en
Priority to JP2000586360A priority patent/JP4607330B2/ja
Priority to PL99348829A priority patent/PL348829A1/xx
Priority to NZ512005A priority patent/NZ512005A/xx
Priority to PCT/GB1999/004135 priority patent/WO2000033870A2/en
Priority to CA2354046A priority patent/CA2354046C/en
Priority to KR1020017007095A priority patent/KR100612552B1/ko
Priority to ES99959548T priority patent/ES2315024T3/es
Priority to AU16687/00A priority patent/AU777969B2/en
Priority to EP99959548A priority patent/EP1137434B1/en
Priority to US09/857,690 priority patent/US6699483B1/en
Priority to DE69939837T priority patent/DE69939837D1/de
Priority to MXPA01005815A priority patent/MXPA01005815A/es
Priority to HU0104857A priority patent/HUP0104857A3/hu
Priority to IL14329599A priority patent/IL143295A0/xx
Priority to CZ20012033A priority patent/CZ20012033A3/cs
Priority to AT99959548T priority patent/ATE412425T1/de
Priority to NZ527763A priority patent/NZ527763A/en
Priority to IL143295A priority patent/IL143295A/en
Priority to ZA200104163A priority patent/ZA200104163B/en
Priority to NO20012818A priority patent/NO326035B1/no
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
GBGB9827103.4A 1998-12-10 1998-12-10 New cancer treatments Ceased GB9827103D0 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
GBGB9827103.4A GB9827103D0 (en) 1998-12-10 1998-12-10 New cancer treatments
NZ527763A NZ527763A (en) 1998-12-10 1999-12-09 Allogeneic immunotherapeutic agent comprising three human prostate tumour cell lines derived from three different primary tumours useful in treating prostate cancer
US09/857,690 US6699483B1 (en) 1998-12-10 1999-12-09 Cancer treatments
MXPA01005815A MXPA01005815A (es) 1998-12-10 1999-12-09 Nuevos tratamientos para el cancer.
NZ512005A NZ512005A (en) 1998-12-10 1999-12-09 New cancer treatments
PCT/GB1999/004135 WO2000033870A2 (en) 1998-12-10 1999-12-09 New cancer treatments
CA2354046A CA2354046C (en) 1998-12-10 1999-12-09 New cancer treatments
KR1020017007095A KR100612552B1 (ko) 1998-12-10 1999-12-09 새로운 암치료법
ES99959548T ES2315024T3 (es) 1998-12-10 1999-12-09 Nuevos tratamientos para el cancer.
AU16687/00A AU777969B2 (en) 1998-12-10 1999-12-09 New cancer treatments
EP99959548A EP1137434B1 (en) 1998-12-10 1999-12-09 New cancer treatments
JP2000586360A JP4607330B2 (ja) 1998-12-10 1999-12-09 ガンの新規処置
DE69939837T DE69939837D1 (de) 1998-12-10 1999-12-09 Neue krebsbehandlung
PL99348829A PL348829A1 (en) 1998-12-10 1999-12-09 New cancer treatments
HU0104857A HUP0104857A3 (en) 1998-12-10 1999-12-09 New cancer treatments
IL14329599A IL143295A0 (en) 1998-12-10 1999-12-09 New cancer treatments
CZ20012033A CZ20012033A3 (cs) 1998-12-10 1999-12-09 Nové způsoby léčby zhoubného bujení
AT99959548T ATE412425T1 (de) 1998-12-10 1999-12-09 Neue krebsbehandlung
ZA200104163A ZA200104163B (en) 1998-12-10 2001-05-22 New cancer treatments.
IL143295A IL143295A (en) 1998-12-10 2001-05-22 Immunological substances and preparations containing them for the treatment of cancer
NO20012818A NO326035B1 (no) 1998-12-10 2001-06-07 Allogent immunterapeutisk middel, agens, sammensetning og vaksine for behandling av prostatakreft, og anvendelse av disse.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9827103.4A GB9827103D0 (en) 1998-12-10 1998-12-10 New cancer treatments

Publications (1)

Publication Number Publication Date
GB9827103D0 true GB9827103D0 (en) 1999-02-03

Family

ID=10843925

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9827103.4A Ceased GB9827103D0 (en) 1998-12-10 1998-12-10 New cancer treatments

Country Status (19)

Country Link
US (1) US6699483B1 (https=)
EP (1) EP1137434B1 (https=)
JP (1) JP4607330B2 (https=)
KR (1) KR100612552B1 (https=)
AT (1) ATE412425T1 (https=)
AU (1) AU777969B2 (https=)
CA (1) CA2354046C (https=)
CZ (1) CZ20012033A3 (https=)
DE (1) DE69939837D1 (https=)
ES (1) ES2315024T3 (https=)
GB (1) GB9827103D0 (https=)
HU (1) HUP0104857A3 (https=)
IL (2) IL143295A0 (https=)
MX (1) MXPA01005815A (https=)
NO (1) NO326035B1 (https=)
NZ (1) NZ512005A (https=)
PL (1) PL348829A1 (https=)
WO (1) WO2000033870A2 (https=)
ZA (1) ZA200104163B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1272617T3 (da) * 2000-04-01 2011-08-22 Onyvax Ltd Prostata cellelinier og deres anvendelse
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
CA2950109C (en) 2000-10-27 2019-02-19 John W. Hadden Vaccine immunotherapy for immune suppressed patients
ATE421328T1 (de) * 2002-02-22 2009-02-15 Intracel Recources Llc Sterile immunogene nicht-tumorigene tumorzell- zusammensetzungen und verfahren
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
US20050019336A1 (en) 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment
AU2004270113A1 (en) * 2003-08-26 2005-03-17 Becton, Dickinson And Company Methods for intradermal delivery of therapeutics agents
EP2591786B1 (en) 2003-10-16 2017-04-12 Cancure Limited Immunomodulating compositions and uses therefor
US8257715B1 (en) 2004-08-26 2012-09-04 University Of Notre Dame Tissue vaccines and uses thereof
EP3072522B1 (en) 2005-01-06 2019-04-24 Novo Nordisk A/S Anti-kir combination treatments and methods
US8778360B2 (en) * 2005-10-27 2014-07-15 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US8802113B2 (en) * 2005-10-27 2014-08-12 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US9308252B2 (en) * 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US8778362B2 (en) 2005-10-27 2014-07-15 University Of Notre Dame Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof
GB0601598D0 (en) * 2006-01-26 2006-03-08 Stathopoulos Apostolos Method
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
WO2010053772A2 (en) 2008-10-29 2010-05-14 The Regents Of The University Of California Disease-associated antigens and methods of use thereof
MX2011012147A (es) 2009-05-15 2012-06-19 Irx Therapeutics Inc Inmunoterapia de vacuna.
CN103097543A (zh) 2009-12-08 2013-05-08 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
US8846059B2 (en) 2009-12-08 2014-09-30 University Of Notre Dame Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer
US20110150934A1 (en) * 2009-12-18 2011-06-23 University Of Notre Dame Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer
CN105850982B (zh) * 2016-04-29 2018-08-17 绍兴市人民医院 一种新型组织冻存液
CN105850981B (zh) * 2016-04-29 2018-07-20 绍兴市人民医院 冻存肿瘤组织的方法
EP4006145A4 (en) * 2019-07-24 2023-08-23 Slbigen Inc. Method for preparation of immortalized stem cell line and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
WO1997024132A1 (en) 1995-12-28 1997-07-10 The Johns Hopkins University School Of Medicine Allogeneic paracrine cytokine tumor vaccines
WO1997028255A1 (en) * 1996-02-02 1997-08-07 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer
CA2349217C (en) * 1998-11-03 2012-07-31 Johns Hopkins University Cancer-associated antigens and methods of their identification
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments

Also Published As

Publication number Publication date
AU777969B2 (en) 2004-11-04
NO20012818L (no) 2001-06-07
WO2000033870A2 (en) 2000-06-15
JP2002531521A (ja) 2002-09-24
CA2354046C (en) 2011-02-15
KR20010090873A (ko) 2001-10-19
HUP0104857A3 (en) 2004-04-28
WO2000033870A3 (en) 2000-08-17
AU1668700A (en) 2000-06-26
NZ512005A (en) 2004-01-30
NO326035B1 (no) 2008-09-01
EP1137434B1 (en) 2008-10-29
ZA200104163B (en) 2002-02-04
ES2315024T3 (es) 2009-03-16
PL348829A1 (en) 2002-06-17
EP1137434A2 (en) 2001-10-04
IL143295A0 (en) 2002-04-21
JP4607330B2 (ja) 2011-01-05
US6699483B1 (en) 2004-03-02
IL143295A (en) 2006-04-10
CZ20012033A3 (cs) 2001-10-17
NO20012818D0 (no) 2001-06-07
CA2354046A1 (en) 2000-06-15
KR100612552B1 (ko) 2006-08-11
HUP0104857A2 (hu) 2002-04-29
MXPA01005815A (es) 2003-04-02
DE69939837D1 (de) 2008-12-11
ATE412425T1 (de) 2008-11-15

Similar Documents

Publication Publication Date Title
GB9827103D0 (en) New cancer treatments
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
MX2021005398A (es) Terapia del cancer con celulas inmunitarias anti-cd33.
JP2006525995A5 (https=)
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy
DE69534946D1 (de) Verwendung von nackten Polynukleotiden zur Herstellung eines Medikaments für die Behandlung von Tumoren
AU2003302892A8 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
IL231810A (en) History of itensinoid and pharmaceutical preparations containing the same methods of preparation and use thereof for cancer treatment
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
WO2004112825A3 (en) Combinations of tumor-associated antigens for the treatment of various types of cancers
WO2003097835A3 (en) Pharmaceutical compositions for the treatment of cancer
WO2007147128A3 (en) Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
TW200612988A (en) Adjuvant therapy with the use of anti-glypican 3 antibody
BRPI0612334A2 (pt) uso de uma abordagem baseada em galectina-1 direcionada para rnai no tratamento do cÂncer
Nikolsky Break in the cosmic ray spectrum or confinement violation near 10 6 TeV?
WO2000033869A3 (en) Use of human prostrate cell lines in cancer treatment
WO2011056566A3 (en) Compounds and methods for treatment of cancer
WO2000033871A3 (en) Use of human prostate tumour cell lines in cancer treatment
WO2005051990A3 (en) Polynucleotides overexpressed in breast cancer cells, compositions and methods for the therapy and diagnosis of breast cancer
Yang et al. Effect of chronic endogenous antigen stimulation on CAR T cell persistence and memory formation
WO2004015063A3 (en) Amplification and overexpression of oncogenes
GB2419530A (en) Human prostate cell lines in cancer treatment
EP1351967A4 (en) COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS OF LUNG CANCER
Kerr A United Kingdom coordinating committee on cancer research study of adjuvant chemotherapy for colorectal cancer: preliminary results
AU2003293665A8 (en) Compositions and methods for treating cancer using cytotoxic cd44 antibody immunoconjugates and radiotherapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)